Corporate News
Devyser Diagnostics (DVYSR.ST) closed flat on the 24‑hour period ending 02:24 AM Central European Time on Friday, 23 March. The share price remains anchored around SEK 50 on major exchanges, with a current circulating supply of 16.8 million shares and a market capitalization of SEK 847.8 million. Over the past 24 hours, the stock has seen a modest trade volume of approximately SEK 1.4 million.
Since the close of the last month, Devyser Diagnostics has slipped –4.36 %. The 200‑day simple moving average stands at SEK 78.59, underscoring a long‑term trend below the current trading level. The 52‑week high reached SEK 139.8 on 27 October 2025, while the low dipped to SEK 48.5 on 15 October 2026, indicating a sizeable range that the current price sits near the lower end of.
Peer Performance Snapshot (Last 24 Hours)
| Ticker | Recent % Move | Current Price (SEK) | Market Cap (SEK) | P/E Ratio |
|---|---|---|---|---|
| FIRE.ST | +1.52 % | 167 | 999.2 M | 18.17 |
| CTEK.ST | –2.41 % | 12.66 | 908.3 M | 26.3 |
| SEDANA.ST | +1.12 % | 9.52 | 958.6 M | — |
| MVIR.ST | –1.32 % | 1.5 | 929.8 M | — |
| CRNO-B.ST | –5.99 % | 3.17 | 1 B | — |
Devyser Diagnostics sits among peers that are broadly flat or slightly down, with Firefly and Sedana Medical showing modest gains, whereas Ctek, Medivir, and Cereno Scientific have experienced declines. The relative stability of Devyser’s trading price amidst mixed sector movements suggests a consolidation phase.
Strategic Outlook
Devyser Diagnostics AB, headquartered in Hagersten, Sweden, specializes in diagnostic kits for complex DNA testing across hereditary diseases, oncology, and transplantation. The firm’s product suite targets a European market that demands high‑precision genetic analysis, positioning it advantageously as precision medicine expands. The company’s initial public offering on 10 December 2021 has since cultivated a shareholder base that reflects confidence in its niche technology.
Looking forward, the firm’s pipeline and potential for expanding into additional indications could drive future revenue growth. Analysts are monitoring the company’s ability to translate its specialized technology into scalable, revenue‑generating solutions, especially as demand for genetic diagnostics continues to rise across the region.
For deeper insight into Devyser’s offerings and corporate updates, visit the company’s website at www.devyser.com .